The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
ADC Therapeutics, Inc. Common H0036K147 17,803 539,648 SH   SOLE   539,648 0 0
Autolus Therapeutics Limited Common 05280R100 463 39,740 SH   SOLE   39,740 0 0
Epizyme, Inc. Common 29428V104 34,057 2,854,737 SH   SOLE   2,854,737 0 0
G1 Therapeutics, Inc. Common 3621LQ109 16,445 1,423,794 SH   SOLE   1,423,794 0 0
Harpoon Therapeutics, Inc. Common 41358P106 66,234 3,898,422 SH   SOLE   3,898,422 0 0
iTeos Therapeutics, Inc. Common 46565G104 58,112 2,355,557 SH   SOLE   2,355,557 0 0
MEI Pharma, Inc. Common 552798202 31,630 10,137,859 SH   SOLE   10,137,859 0 0
Merus N.V. Common N5749R100 8,411 700,879 SH   SOLE   700,879 0 0
Repare Therapeutics, Inc. Common 760273102 73,489 2,388,337 SH   SOLE   2,388,337 0 0
TCR2 Therapeutics, Inc. Common 87808K106 68,498 3,370,982 SH   SOLE   3,370,982 0 0
Turning Point Therapeutics, Inc. Common 90041T108 26,967 308,686 SH   SOLE   308,686 0 0
YmAbs Therapeutics, Inc. Common 984241109 12,949 337,291 SH   SOLE   337,291 0 0